拉米夫定联合苷必妥治疗慢性乙型肝炎病人的近期疗效

To evaluate the short-term effect and safety of Lamivudine with GanBiTuo (Transfer Factor against Hepatitis B) treatment in chronic hepatitis B patients.31 patients with chronic hepatitis B enrolled were randomized into observed goup (16 cares) , which were administered Lamivudine 100mg and GanBiTuo.1mg daily for 12 weeks, and control group (15cares) , which were adnimisteral Lamivudine 100mg daily for 12 weeks.The liver function and HBV markers were examined.There were no significant difference between the HBVDNA response rate of two groups (100% VS 80.0%, P>0.05) .HBeAg response rate in obrerved group was higher than in control group (87.5% VS 26.7%, P<0.01) .Proportion of HBeAg/anti-HBe seroconversion had difference between two groups (78.6% VS 25.0%, P<0.05) .ALT normalization rate in observed grop was higher than in control group (100% vs 66.7%, P<0.05) .There was few drug-related adverse event.HBV replication could be inhibited by short-term treatment with Lamivudine/GanBiTuo accompanied with good efficacy and safety.